Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | — | — | — | — | — | — | — | — | — |
| Operating income | -$6.07M | -$4.44M | -$6.98M | -$4.10M | -$3.83M | -$3.62M | -$4.39M | -$6.46M | -$8.52M | -$4.38M |
| Net income | -$6.06M | -$4.44M | -$6.83M | -$4.07M | -$3.83M | -$3.55M | -$4.24M | -$4.32M | $334K | $30.7M |
| EPS (diluted) | -$0.01 | -$0.01 | -$0.01 | $0.00 | -$4.23 | -$2.45 | -$0.27 | -$0.22 | -$1.80 | $3.19 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.35M | -$3.34M | -$5.08M | -$2.88M | -$2.34M | -$3.33M | -$4.12M | -$3.79M | -$2.15M | -$2.98M |
| Share buybacks | — | — | — | — | — | — | $0.00 | $13.6M | $28.2M | $2.54M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | — | $895K | $2.20M | $85.4M | $68.0M | $50.2M | $15.2M |
| Total assets | $7.16M | $8.67M | $6.41M | $5.78M | $6.17M | $7.40M | $90.6M | $73.3M | $59.9M | $55.2M |
| Total liabilities | $638K | $580K | $644K | $743K | $1.08M | $725K | $704K | $587K | $20.4M | $3.28M |
| Shareholders' equity | $6.52M | $8.09M | $5.77M | $5.04M | $5.09M | $6.68M | $89.9M | $72.7M | $27.6M | $51.9M |
| Retained earnings | -$84.7M | -$89.1M | -$96.0M | -$100M | -$104M | -$107M | -$112M | -$116M | -$116M | -$85.0M |
| Shares (wtd avg diluted) | 752M | 845M | 969M | 1.10B | 904K | 1.45M | 15.5M | 19.5M | 9.58M | 7.33M |
Every figure is extracted from PharmaCyte Biotech, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.